Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

This company has been moved to the archive! The financial data has not been updated since February 15, 2024.

Cash Flow Statement 
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Vertex Pharmaceuticals Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income 968,800 1,035,300 915,700 699,800 818,900 930,500 810,500 762,100 770,110 851,928 66,924 653,138 604,190 667,434 837,270 602,753 583,234 57,518 267,427 268,631
Stock-based compensation expense 208,600 130,900 119,300 122,400 111,500 135,600 113,900 130,300 118,608 102,996 104,622 115,174 97,027 99,539 117,189 115,706 91,591 85,420 89,687 93,791
Depreciation expense 59,000 42,100 41,400 38,800 38,400 36,700 37,300 35,900 33,832 31,696 31,238 28,834 29,355 26,642 26,697 26,821 26,256 25,847 27,698 27,140
Deferred income taxes (131,000) (115,500) (176,600) (113,400) 148,100 (182,300) (229,400) (12,300) (41,946) 68,241 (237,938) 57,043 212,231 56,147 (27,742) 36,705 73,212 6,817 43,933 43,425
(Gains) losses on equity securities 400 6,200 400 (6,400) 6,000 (16,700) 84,200 75,600 (12,107) (46,679) (10,609) 52,295 (171,071) (75,750) (109,986) 44,870 (128,735) 31,216 (56,527) (43,551)
Increase (decrease) in fair value of contingent consideration (50,300) 1,200 (600) (1,900) 1,800 (2,600) (49,200) (7,500) (2,000) 1,200 1,600 (3,900) 500 1,800 9,200 1,600 1,500 2,959
Other non-cash items, net 18,000 (20,700) (10,600) 21,700 44,600 (26,500) (11,200) 4,900 (6,188) 9,402 8,854 2,332 26,461 36,064 6,639 9,668 20,966 (10,030) 8,437 (2,431)
Accounts receivable, net 15,400 (6,100) (2,900) (90,500) 10,200 (119,500) (84,100) (165,200) (43,534) (185,318) 52,525 (98,373) (72,253) 12,948 59,533 (223,672) (184,143) 14,426 (25,734) (30,136)
Inventories (70,000) (97,500) (72,800) (82,600) (78,300) (26,800) (33,300) 2,000 (26,973) (18,335) (24,707) (22,785) (37,107) (30,521) (36,936) (27,450) (18,767) (20,106) (12,035) (13,139)
Prepaid expenses and other assets (451,300) (121,000) (19,600) 46,200 (284,500) (127,200) 17,700 67,600 15,872 (15,485) (78,868) (13,319) (32,653) (235,986) (31,713) 2,790 59,149 (6,129) (25,521) 7,941
Accounts payable (31,800) 9,200 35,600 35,700 159,900 (69,900) 45,300 (14,500) 53,943 2,302 (13,701) (10,644) 35,123 1,456 412 14,285 (10,575) 15,864 (3,929) (24,145)
Accrued expenses (356,700) 368,700 276,700 140,700 (437,800) 433,200 485,500 61,600 51,243 146,631 (45,457) 152,983 (328,886) 81,233 216,037 153,814 (82,818) 141,731 141,247 (27,279)
Other liabilities 55,500 35,600 28,400 89,400 539,600 (9,000) (47,400) 15,700 84,133 (21,360) (54,250) 8,277 128,615 266,742 (28,073) 57,808 15,138 (10,744) 9,066 24,537
Changes in operating assets and liabilities (838,900) 188,900 245,400 138,900 (90,900) 80,800 383,700 (32,800) 134,684 (91,565) (164,458) 16,139 (307,161) 95,872 179,260 (22,425) (222,016) 135,042 83,094 (62,221)
Adjustments to reconcile net income to net cash provided by operating activities (734,200) 233,100 218,700 200,100 259,500 25,000 329,300 194,100 224,883 75,291 (266,691) 267,917 (112,658) 240,314 201,257 212,945 (137,226) 277,271 196,322 56,153
Net cash provided by operating activities 234,600 1,268,400 1,134,400 899,900 1,078,400 955,500 1,139,800 956,200 994,993 927,219 (199,767) 921,055 491,532 907,748 1,038,527 815,698 446,008 334,789 463,749 324,784
Purchases of available-for-sale debt securities (988,500) (407,200) (574,200) (1,816,600) (274,900) (189,900) (110,800) (117,100) (80,441) (208,301) (118,003) (121,455) (184,459) (120,360) (51,312) (75,265) (155,457) (118,103) (135,421) (128,215)
Sales and maturities of available-for-sale debt securities 218,100 331,200 239,800 50,000 484,100 193,600 112,600 129,700 47,167 230,862 103,199 118,072 187,923 39,024 85,250 60,145 100,779 146,438 121,589 107,118
Purchases of property and equipment (58,100) (40,600) (59,600) (42,100) (33,600) (54,200) (53,300) (63,600) (61,715) (52,522) (49,837) (70,926) (47,689) (174,795) (17,864) (19,450) (16,761) (24,291) (16,358) (18,041)
Sale of equity securities 95,100 287,972 21,721 55,838 72,036 94,936
Investment in equity securities and notes receivable (1,100) (5,000) (24,900) (37,800) (10,000) (39,009) (22,991) (15,000) (13,527) (5,800) (12,100) (7,219) (20,000)
Payments related to finite-lived intangible assets (58,000)
Payment to acquire business, net of cash acquired (295,900) (908,388) (245,824)
Net cash (used in) provided by investing activities (886,500) (117,700) (303,900) (1,833,600) 175,600 (384,200) (61,500) (51,000) (133,998) (52,952) (79,641) (74,309) 243,747 (247,937) 71,912 31,666 (896,991) (248,999) (50,190) (39,138)
Issuances of common stock under benefit plans 46,400 15,400 58,600 14,200 51,600 36,600 64,400 33,700 34,711 13,795 37,935 15,559 30,092 21,796 133,461 79,597 198,614 30,538 50,472 63,620
Repurchases of common stock (149,500) (117,000) (28,300) (132,800) (368,175) (632,273) (424,952) (131,103) (108,007) (300,026) (36,003) (56,010) (94,007)
Payments in connection with common stock withheld for employee tax obligations (3,200) (53,200) (3,100) (166,600) (2,100) (48,000) (4,400) (117,500) (1,677) (28,559) (3,524) (102,140) (20,496) (40,528) (3,080) (136,167) (59) (104) (5,832)
Payments on finance leases (12,000) (11,300) (11,000) (10,600) (10,400) (49,500) (12,700) (12,900) (12,408) (12,057) (10,302) (12,233) (10,897) (10,648) (10,443) (10,287) (10,306) (9,953) (9,541) (9,385)
Proceeds from finance leases 9,953 1,022 7,993 3,632 4,609 2,809 5,833 9,044 1,002
Other financing activities (1,500) 1,100 1,100 1,100 1,100 700 400 1,300 1,361 1,411 1,448 1,480 2,603 (6,106) 87 1,620 131 (125) 1,062 3,615
Net cash provided by (used in) financing activities (119,800) (165,000) 17,300 (294,700) 40,200 (60,200) 47,700 (95,400) (336,235) (656,661) 33,550 (518,654) (125,192) (140,684) 120,025 (359,430) 161,421 20,356 (13,015) (41,989)
Effect of changes in exchange rates on cash 27,400 (22,500) 10,000 12,000 40,800 (38,200) (25,900) (5,900) (4,928) (8,461) 4,019 (4,030) 17,773 6,158 3,272 (6,651) 5,652 (3,201) (430) (378)
Net increase (decrease) in cash, cash equivalents and restricted cash (744,300) 963,200 857,800 (1,216,400) 1,335,000 472,900 1,100,100 803,900 519,832 209,145 (241,839) 324,062 627,860 525,285 1,233,736 481,283 (283,910) 102,945 400,114 243,279

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Vertex Pharmaceuticals Inc. net cash provided by operating activities increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Vertex Pharmaceuticals Inc. net cash (used in) provided by investing activities increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Vertex Pharmaceuticals Inc. net cash provided by (used in) financing activities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.